These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25313760)

  • 21. [Comparison of platinum-containing doublet chemotherapy and liposome paclitaxel monotherapy for the treatment of elderly patients with advanced non-small cell lung cancer].
    Wang C; Zhou L; Liu YM; Ding ZY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Jul; 44(4):685-8. PubMed ID: 24059133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular detection and prognostic value of epithelial markers mRNA expression in peripheral blood of advanced non-small cell lung cancer patients.
    Arrieta O; Pineda B; Muñiz-Hernández S; Flores D; Ordóñez G; Borbolla-Escoboza JR; Orta D
    Cancer Biomark; 2014; 14(4):215-23. PubMed ID: 24934364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
    J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
    Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
    Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
    Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
    Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer.
    De Vita F; Orditura M; Auriemma A; Infusino S; Roscigno A; Catalano G
    Oncol Rep; 1998; 5(3):649-52. PubMed ID: 9538169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
    Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C
    Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
    Gautschi O; Hugli B; Ziegler A; Bigosch C; Bowers NL; Ratschiller D; Jermann M; Stahel RA; Heighway J; Betticher DC
    Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC.
    Kim SH; Cho BC; Choi HJ; Chung KY; Kim DJ; Park MS; Kim SK; Chang J; Shin SJ; Sohn JH; Kim JH
    Lung Cancer; 2008 Jun; 60(3):393-400. PubMed ID: 18155802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
    Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
    Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.
    Krzakowski M; Ramlau R; Jassem J; Szczesna A; Zatloukal P; Von Pawel J; Sun X; Bennouna J; Santoro A; Biesma B; Delgado FM; Salhi Y; Vaissiere N; Hansen O; Tan EH; Quoix E; Garrido P; Douillard JY
    J Clin Oncol; 2010 May; 28(13):2167-73. PubMed ID: 20351334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serological investigation of the clinical significance of fascin in non-small-cell lung cancer.
    Teng Y; Xu S; Yue W; Ma L; Zhang L; Zhao X; Guo Y; Zhang C; Gu M; Wang Y
    Lung Cancer; 2013 Nov; 82(2):346-52. PubMed ID: 24070574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
    Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
    Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancer.
    Kim YH; Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Nishiwaki Y
    Respir Med; 2010 Mar; 104(3):434-9. PubMed ID: 19913397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma D-Dimer Level Correlates with Age, Metastasis, Recurrence, Tumor-Node-Metastasis Classification (TNM), and Treatment of Non-Small-Cell Lung Cancer (NSCLC) Patients.
    Guo J; Gao Y; Gong Z; Dong P; Mao Y; Li F; Rong J; Zhang J; Zhou Y; Feng H; Guo H; Gu L; An M; Wen K; Zhang J
    Biomed Res Int; 2021; 2021():9623571. PubMed ID: 34712737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and prognostic importance of XIAP and USP8 in advanced stages of non-small cell lung cancer.
    Baykara M; Yaman M; Buyukberber S; Tufan G; Demirci U; Benekli M; Coskun U; Ozet A; Umit Bagriacik E
    J BUON; 2013; 18(4):921-7. PubMed ID: 24344018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression of serum breast drug-resistance protein in predicting chemosensitivity of NSCLC].
    Hu Y; Feng FY; Cheng SJ; Gao YN; Xiao T; Liu YN
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):750-2. PubMed ID: 17366786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
    Shen J; Ye Y; Chang DW; Huang M; Heymach JV; Roth JA; Wu X; Zhao H
    Lung Cancer; 2017 Dec; 114():70-78. PubMed ID: 29173770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. XBP1 promoter polymorphism modulates platinum-based chemotherapy gastrointestinal toxicity for advanced non-small cell lung cancer patients.
    Peng J; Chen YY; Yang LX; Zhao XY; Gao ZQ; Yang J; Wu WT; Wang HJ; Wang JC; Qian J; Chen HY; Jin L; Bai CX; Han BH; Lu DR
    Lung Cancer; 2013 Jun; 80(3):333-8. PubMed ID: 23510626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.